Stock 4889 RENASCIENCE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Renascience Inc.

Equities

4889

JP3981100005

Pharmaceuticals

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-04-30 am EDT 		5-day change 1st Jan Change
350 JPY +0.86% Intraday chart for Renascience Inc. +2.04% -19.35%
2022 Certain Common Stock of Renascience Inc. are subject to a Lock-Up Agreement Ending on 22-MAR-2022. CI
2021 Certain Common Stock of Renascience Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2021. CI

Valuation

Fiscal Period: Marzo 2022 2023
Capitalization 1 5,669 5,695
Enterprise Value (EV) 1 3,482 3,792
P/E ratio -20 x -17 x
Yield - -
Capitalization / Revenue 40.8 x 56.9 x
EV / Revenue 25.1 x 37.9 x
EV / EBITDA -16,742,395 x -11,386,912 x
EV / FCF -23,216,121 x -23,736,098 x
FCF Yield -0% -0%
Price to Book 2.57 x 3.05 x
Nbr of stocks (in thousands) 12,712 12,712
Reference price 2 446.0 448.0
Announcement Date 6/30/22 6/30/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2020 2021 2022 2023
Net sales 1 72 209 139 100
EBITDA - - -208 -333
EBIT 1 -183 -85 -211 -334
Operating Margin -254.17% -40.67% -151.8% -334%
Earnings before Tax (EBT) 1 -184 -100 -253 -334
Net income 1 -184 -100 -254 -335
Net margin -255.56% -47.85% -182.73% -335%
EPS 2 -18.74 -10.18 -22.30 -26.35
Free Cash Flow - - -150 -159.8
FCF margin - - -107.91% -159.75%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 8/18/21 8/18/21 6/30/22 6/30/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 S1 2023 Q3 2024 Q1 2024 S1 2024 Q3
Net sales - 31 35 73 20 20 10 93 120 -
EBITDA - - - - - - - - - -
EBIT 1 -58.66 -91 -42 -77 -63 -152 -73 2 -94 -127
Operating Margin - -293.55% -120% -105.48% -315% -760% -730% 2.15% -78.33% -
Earnings before Tax (EBT) 1 -86.38 -119 -45 -89 -63 -152 -73 2 -94 -127
Net income 1 -86.11 -119 -45 -90 -63 -153 -73 2 -95 -127
Net margin - -383.87% -128.57% -123.29% -315% -765% -730% 2.15% -79.17% -
EPS 2 - -11.78 -3.260 - -5.000 -12.10 -5.730 0.1700 -7.500 -10.00
Dividend per Share - - - - - - - - - -
Announcement Date 11/11/21 11/11/21 2/14/22 5/12/22 8/10/22 11/10/22 2/9/23 8/10/23 11/9/23 2/8/24
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 600 550 2,187 1,903
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - -150 -160
ROE (net income / shareholders' equity) - -16.9% -18.4% -16.5%
ROA (Net income/ Total Assets) - -5.11% -7.53% -8.86%
Assets 1 - 1,956 3,374 3,781
Book Value Per Share 2 63.20 57.10 173.0 147.0
Cash Flow per Share 2 99.80 104.0 188.0 174.0
Capex - - 1 2
Capex / Sales - - 0.72% 2%
Announcement Date 8/18/21 8/18/21 6/30/22 6/30/23
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
RENASCIENCE INC. Stock Renascience Inc.
-19.35% 28.15M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 234B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 196B
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4889 Stock
  4. Financials Renascience Inc.